Drug targeting the dynamics of opioid systems in alcohol dependence
针对酒精依赖中阿片类药物系统动态的药物
基本信息
- 批准号:10443881
- 负责人:
- 金额:$ 51.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-20 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AbstinenceAcuteAffectAlcohol abuseAlcohol consumptionAlcohol dependenceAmygdaloid structureAnimal BehaviorAnimal ModelAnimalsAttenuatedAutopsyBehavioralBindingBinding SitesBrainCell Culture TechniquesCell NucleusCell membraneCellsChronicClinicalClinical TrialsComplexCountryDataDependenceDoseDrug TargetingDynorphinsElementsEnkephalinsEthanolEthanol dependenceFDA approvedFluorescenceFluorescence SpectroscopyFutureGene ExpressionGenesGenetic PolymorphismGenotypeGlobal ChangeHomoImageImaging TechniquesImmunohistochemistryIn SituIndividualInvestigationLateralLengthLifeLipidsLongevityMedicalMembraneMembrane MicrodomainsMental DepressionMicroscopyModelingMolecularNaltrexoneNegative ReinforcementsNeuronsOpioidOpioid AntagonistOpioid ReceptorPharmaceutical PreparationsPilot ProjectsProteinsPublishingRattusReactionReceptor SignalingRecording of previous eventsRelapseResolutionSavingsScandinavianSignal TransductionSocietiesSpecimenSpectrum AnalysisSystemTechniquesTechnologyTestingTimeTranscriptalcohol effectalcohol exposurealcohol use disorderantagonistbehavioral phenotypingbrain tissueclinical effectclinical examinationcravingdimerdisorder later incidence preventionepidemiology studyfluorescence imaginghedonicindexinginsightinterestkappa opioid receptorsmu opioid receptorsnanoscaleneuropsychiatrynovelovertreatmentpersonalized medicinepreventreceptorsingle moleculesocialtissue preparationtraffickingtranslational approach
项目摘要
PROJECT SUMMARY
Alcohol use disorder (AUD) is a serious condition with severe medical and societal consequences.There has
been little progress in medical treatment over the past decades. We are taking a translational approach and have
established an animal model, where alcohol-dependent rats in various stages of abstinence are subjects of
investigation. The neuronal target is the opioid systems and the opponent hypothesis. We propose that the initial
euphoric effects are channeled through the enkephalin/mu-opioid receptor (MOP) and the later developing
negative reinforcement (craving) is related to activity at the dynorphin/kappa-opioid receptor (KOP). In fact, the
MOP antagonist, naltrexone is a FDA-approved agent with indication to reduce relapse. KOP antagonists are
entering clinical trials in different neuropsychiatric conditions. We have chosen CERC-501 as index drug, being
reversible and apparently well tolerated in clinical examination. After behavioral recordings, brain specimens will
be dissected and form a “brain bank” for further analysis. A focus of interest is the central nucleus of the amygdala
(CeA), and the circuitry presenting MOP and/or KOP. Selected specimens will undergo superresolution
microscopy (quantitative Single Molecule Localization Microscopy, qSMLM). A pilot study showed that already
an acute dose of EtOH disrupts localization of MOP and KOP, an effect blocked by naltrexone. How EtOH affects
receptor mobility in the plasma membrane, receptor clustering (homo- and hetero-dimers) and association with
protein- and lipid-rich membrane domains will be studied by fluorescence correlation spectroscopy (FCS). As
with qSMLM resolution is achieved at the single-molecule level. Both technologies will be used to study co-
localization of receptors with proteins of relevance for the signaling cascade. We hypothesize that EtOH perturbs
the dynamic selforganization of signaling domains harboring MOPs and KOPs, that distinct alterations in
mechanisms controlling MOP vs KOP organization develop during chronic EtOH exposure. With OP antagonists
innate MOP and KOP signaling complexes are stabilized at the nanoscale level. Focused studies of these
mechanisms will provide critical new insight into molecular mechanisms through which EtOH-induced receptor
disruptions may be prevented or reversed. The commensurate importance of the two opioid systems may vary
between individuals and influence the choice of personalized therapy with OP antagonists. Studies will include
the N40D MOP genotype known to affect the behavioral phenotype and sensitivity to naltrexone.
项目总结
酒精使用障碍(AUD)是一种严重的疾病,具有严重的医学和社会后果。
在过去的几十年里,医疗方面几乎没有取得什么进展。我们正在采取翻译方法,并已
建立了一种动物模型,在该模型中,处于不同戒断阶段的酒精依赖大鼠是
调查。神经元的靶点是阿片系统和对手假说。我们建议最初的
兴奋效应是通过脑啡肽/u-阿片受体(MOP)和后来的发育来实现的。
负性强化(渴求)与强啡肽/kappa阿片受体(KOP)的活性有关。事实上,
MOP拮抗剂纳曲酮是FDA批准的一种药物,有减少复发的适应症。KOP对手是
在不同的神经精神状态下进行临床试验。我们选择CERC-501作为指标药物,
可逆,在临床检查中明显耐受性良好。在行为记录之后,大脑样本将
被解剖并形成一个“脑库”,以供进一步分析。人们关注的焦点是杏仁核的中央核。
(CEA),以及呈现MOP和/或KOP的电路。选定的标本将进行超分辨
显微镜(定量单分子定位显微镜,qSMLM)。一项初步研究表明,
急性剂量的乙醇扰乱MOP和KOP的定位,这一作用可被纳曲酮阻断。Etoh如何影响
细胞膜上的受体迁移率、受体聚集(同源和异源二聚体)及其与
富含蛋白质和脂肪的膜结构域将用荧光相关光谱(FCS)进行研究。AS
有了qSMLM,就可以在单分子水平上实现分辨率。这两种技术都将被用于研究联合
受体与与信号级联相关的蛋白质的定位。我们假设Etoh对
含有MOP和KOP的信号域的动态自组织,在
控制MOP和KOP组织的机制在慢性乙醇暴露过程中发展起来。使用OP拮抗剂
天然的MOP和KOP信号复合体在纳米水平上是稳定的。对这些的重点研究
机制将为乙醇诱导受体的分子机制提供关键的新见解
中断是可以防止或扭转的。这两种阿片系统的重要性可能不同。
并影响使用OP拮抗剂进行个性化治疗的选择。研究将包括
已知的N40D MOP基因会影响行为表型和对纳曲酮的敏感性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Remi Martin-Fardon其他文献
Remi Martin-Fardon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Remi Martin-Fardon', 18)}}的其他基金
Cocaine-motivated behaviors: development of novel viral-based strategies to target orexinergic input to the infralimbic cortex.
可卡因驱动的行为:开发基于病毒的新型策略,将食欲素输入瞄准边缘下皮层。
- 批准号:
10447503 - 财政年份:2022
- 资助金额:
$ 51.92万 - 项目类别:
Cocaine-motivated behaviors: development of novel viral-based strategies to target orexinergic input to the infralimbic cortex.
可卡因驱动的行为:开发基于病毒的新型策略,将食欲素输入瞄准边缘下皮层。
- 批准号:
10671018 - 财政年份:2022
- 资助金额:
$ 51.92万 - 项目类别:
Drug targeting the dynamics of opioid systems in alcohol dependence
针对酒精依赖中阿片类药物系统动态的药物
- 批准号:
10032660 - 财政年份:2020
- 资助金额:
$ 51.92万 - 项目类别:
Drug targeting the dynamics of opioid systems in alcohol dependence
针对酒精依赖中阿片类药物系统动态的药物
- 批准号:
10662302 - 财政年份:2020
- 资助金额:
$ 51.92万 - 项目类别:
Drug targeting the dynamics of opioid systems in alcohol dependence
针对酒精依赖中阿片类药物系统动态的药物
- 批准号:
10266772 - 财政年份:2020
- 资助金额:
$ 51.92万 - 项目类别:
Pivotal role of thalamic hypocretin transmission during EtOH seeking and relapse
丘脑下丘脑分泌素传输在乙醇寻找和复发过程中的关键作用
- 批准号:
10436851 - 财政年份:2018
- 资助金额:
$ 51.92万 - 项目类别:
Pivotal role of thalamic hypocretin transmission during EtOH seeking and relapse
丘脑下丘脑分泌素传输在乙醇寻找和复发过程中的关键作用
- 批准号:
10200612 - 财政年份:2018
- 资助金额:
$ 51.92万 - 项目类别:
Dysregulation of thalamic hypocretin transmission following ethanol dependence
乙醇依赖后丘脑下丘脑分泌素传输失调
- 批准号:
9110011 - 财政年份:2016
- 资助金额:
$ 51.92万 - 项目类别:
Cognitive Function in Alcohol Dependence and Protracted Withdrawal
酒精依赖和长期戒断的认知功能
- 批准号:
9303764 - 财政年份:2013
- 资助金额:
$ 51.92万 - 项目类别:
Role of Orexin/Hypocretin in cocaine-seeking behavior
食欲素/下丘脑分泌素在可卡因寻求行为中的作用
- 批准号:
8397500 - 财政年份:2012
- 资助金额:
$ 51.92万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 51.92万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 51.92万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 51.92万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 51.92万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 51.92万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 51.92万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 51.92万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 51.92万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 51.92万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 51.92万 - 项目类别:
Standard Grant